RTW Investments LP grew its position in Corium International Inc (NASDAQ:CORI) by 0.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,923,217 shares of the biopharmaceutical company’s stock after purchasing an additional 12,695 shares during the period. Corium International comprises approximately 1.1% of RTW Investments LP’s holdings, making the stock its 19th biggest holding. RTW Investments LP owned about 5.31% of Corium International worth $15,405,000 as of its most recent filing with the SEC.
Other large investors have also recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new stake in shares of Corium International in the 4th quarter valued at $123,000. DekaBank Deutsche Girozentrale acquired a new stake in shares of Corium International in the 1st quarter valued at $167,000. Engineers Gate Manager LP acquired a new stake in shares of Corium International in the 2nd quarter valued at $215,000. Alps Advisors Inc. acquired a new stake in shares of Corium International in the 2nd quarter valued at $420,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Corium International in the 1st quarter valued at $455,000.
Several brokerages have recently commented on CORI. Zacks Investment Research upgraded shares of Corium International from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price target on shares of Corium International in a report on Monday, August 13th. ValuEngine raised Corium International from a “hold” rating to a “buy” rating in a report on Friday, August 10th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $14.00 price target on shares of Corium International in a report on Friday, August 10th. Finally, BidaskClub raised Corium International from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $12.80.
In other Corium International news, Director Robert Thomas sold 35,608 shares of the business’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $8.86, for a total transaction of $315,486.88. Following the completion of the sale, the director now directly owns 35,608 shares of the company’s stock, valued at approximately $315,486.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Joseph J. Sarret sold 3,565 shares of the business’s stock in a transaction dated Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The disclosure for this sale can be found here. Insiders sold 119,965 shares of company stock valued at $1,060,275 over the last ninety days. 30.80% of the stock is currently owned by company insiders.
Corium International stock opened at $9.59 on Friday. The company has a debt-to-equity ratio of 2.83, a current ratio of 7.61 and a quick ratio of 7.47. Corium International Inc has a 12-month low of $7.17 and a 12-month high of $13.93. The stock has a market capitalization of $354.89 million, a P/E ratio of -5.85 and a beta of 1.60.
Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.04. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. The business had revenue of $7.67 million during the quarter, compared to analysts’ expectations of $6.72 million. sell-side analysts predict that Corium International Inc will post -1.53 EPS for the current fiscal year.
Corium International Company Profile
Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.
Recommended Story: Stop Order Uses For Individual Investors
Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.